Fennec Pharmaceuticals Inc. 8-K Filing
Ticker: FENC · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1211583
| Field | Detail |
|---|---|
| Company | Fennec Pharmaceuticals Inc. (FENC) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Fennec Pharmaceuticals Inc. (ticker: FENC) to the SEC on Dec 2, 2025.
How long is this filing?
Fennec Pharmaceuticals Inc.'s 8-K filing is 2 pages with approximately 538 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-12-02 16:02:26
Filing Documents
- tm2532518d1_8k.htm (8-K) — 27KB
- tm2532518d1_ex99-1.htm (EX-99.1) — 31KB
- tm2532518d1_ex99-1img001.jpg (GRAPHIC) — 2KB
- 0001104659-25-117697.txt ( ) — 234KB
- fencf-20251202.xsd (EX-101.SCH) — 3KB
- fencf-20251202_lab.xml (EX-101.LAB) — 33KB
- fencf-20251202_pre.xml (EX-101.PRE) — 22KB
- tm2532518d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On December 2, 2025, Fennec Pharmaceuticals Inc. issued a news release and announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan. PEDMARK is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 99.1 Press Release dated December 2, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FENNEC PHARMACEUTICALS INC. Date December 2, 2025 By: /s/ Robert Andrade Robert Andrade Chief Financial Officer